• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Research indicates notable future growth in transdermal patch market

March 23, 2021 By Sean Whooley

adhesive microneedle coin-sized insulin patch UCLA diabetes
Researchers were able to preload enough insulin into the coin-sized adhesive microneedle patches to enable clinical use. [Image courtesy of UCLA]
Research published today has highlighted potential growth down the line in the transdermal drug delivery patch space.

Kuick Research published an analysis claiming that the U.S. transdermal patch drug market is revolving on account of two powerful “mega-trends.” Those trends — acceleration in the U.S. pharmaceutical market growth and the restructuring of the healthcare sector to modulate drug delivery mechanisms more efficiently — could promote major growth in the next five years, according to a news release.

The researchers project that the market presents a $6 billion opportunity by 2026 as painless and non-invasive drug delivery methods become more and more sought after and cost-effectiveness and efficiency rise within the drug delivery and pharmaceutical space.

Kuick said the market has already experienced decades of “respectable” growth within a large market size, while it also presents promising business models that offer adaptability to patients.

Growing amounts of resources and technologically-driven innovations are only contributing to the rise of the market, researchers say, as they claim the transdermal patch space is a “constructive sector” for the entire U.S. pharmaceutical market.

The research concludes that, given the factors driving transdermal drug delivery, the overall market in the U.S. can be seen as a “dominant leader” over several decades to come.

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured Tagged With: Drug delivery

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS